SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is ...
GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible ...
GoodRx announced that eligible self-paying patients can now access all strengths of Ozempic and Wegovy pens for $499 per month through its platform, effective immediately. The collaboration marks the ...
TrumpRx launched with more than 40 medications at discounted prices after negotiations with more than a dozen drug companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results